Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours

BACKGROUND: Preclinical studies suggest that histone deacetylase (HDAC) inhibitors may restore tumour sensitivity to retinoids. The objective of this study was to determine the safety, tolerability, and the pharmacokinetic (PK)/pharmacodynamic (PD) profiles of the HDAC inhibitor entinostat in combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Pili, R, Salumbides, B, Zhao, M, Altiok, S, Qian, D, Zwiebel, J, Carducci, M A, Rudek, M A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251867/
https://www.ncbi.nlm.nih.gov/pubmed/22134508
http://dx.doi.org/10.1038/bjc.2011.527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251867/
https://www.ncbi.nlm.nih.gov/pubmed/22134508
http://dx.doi.org/10.1038/bjc.2011.527

Ejemplares similares